Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Xtandi (enzalutamide; Pfizer/Astellas) Drug Analysis: An Androgen Receptor (AR) Signaling Inhibitor that Inhibits The AR at Three Distinct Points in the Signaling Pathway - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Xtandi" drug pipelines has been added to ResearchAndMarkets.com's offering.

Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA. In preclinical studies, Xtandi was shown to provide a more complete suppression of the AR than Casodex (bicalutamide; AstraZeneca).

Market Data

List of Figures

Figure 1: Xtandi for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Xtandi for prostate cancer

Figure 3: Drug assessment summary of Xtandi for prostate cancer

Figure 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Xtandi drug profile

Table 2: Xtandi Phase III data in prostate cancer

Table 3: Xtandi Phase III trials in prostate cancer

Table 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sdmwrs/2018_xtandi?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005578/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.